Wayne said he would keep all 3 options open but did say at one stage he would like to take this to market. I got the impression when we see the approved protocol for the FDA trial it will have less patients and be over a shorter time span than many here have predicted. The Vin V study is being included with the main study, which will be a non inferiority trial against the Medtronic and Edwards valve. As our data shows a 30% improvement on these valves the sample numbers will be modest to prove non inferiority. I was very optimistic after hearing about this trial info and expect a jump in share price when the protocol is announced. I believe he also said the trial would only cost USD 30m.
AVR Price at posting:
$18.95 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)